Monday, August 31, 2026

STOP The Sellout: China’s Xi Puts U.S. Security at Risk by Plotting to END Korea’s Anti-Communist Sanctions

Xi Jinping's upcoming visit to South Korea aims to normalize relations and discuss cultural exchanges, trade, and North Korean issues.

AN EXPOSED HORIZON : The Hidden Impact Of America’s Middle East Pivot On Korean Security

U.S. Forces Korea plans to redeploy THAAD systems from South Korea to the Middle East, but South Korea assures its defense remains strong.

Korean Entrepreneurs Invited to VIP Lunch with Trump at the $TRUMP Meme Coin Conference

Korean entrepreneurs Lee Seung-yoon and Song Chi-hyung to speak at Trump's event for meme coin holders, discussing AI and data infrastructure.

Tag: Samsung Bioepis

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Samsung Bioepis, Built on Biosimilars, Expands Growth Strategy Into Novel Drugs

Samsung Bioepis is pursuing a two-track growth strategy that combines global biosimilar expansion with next-generation novel drug development, including ADC therapies.

AI-Powered Antibody Drug Development: Samsung Biologics and Protina’s Game-Changing License Agreement

Samsung Bioepis and Protina sign a licensing agreement to develop AI-designed antibody drugs, aiming for candidates by 2027.

Samsung Bioepis Signs Teva Deal to Commercialize Opuviz in Canada, Expanding North American Biosimilar Business

Samsung Bioepis partners with Teva to launch ophthalmology biosimilar Opuviz in Canada, enhancing access to treatments for patients.

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

Samsung Bioepis Expands SB15 Eylea Rival: Licensing Pact Targets Global Markets as Original Drug Hits $10.5B Sales

Samsung Bioepis has secured a licensing deal for its ophthalmic treatment SB15, expanding access in international markets outside the US and Canada.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.